Founded in 1997, Tecport Optics designs, manufactures, sells and services state-of-the-art thin film vacuum deposition systems to customers across the globe. Working vigorously with its world-class instrument suppliers, Tecport builds the most reliable, efficient, and flexible coating systems in the world, customized to the meet the technical specifications of a variety of industries. Dedicated to excellence in customer service and technical innovation, Tecport has built a loyal customer base that benefits from its corporate motto,
We Serve to Serve Again
New Partners MTSU, Tecport Optics May Revolutionize Medical Research, Health Care with Diagnostic Tool
October 12, 2016 — Middle Tennessee State University and Tecport Optics of Orlando, Florida, have entered into a licensing agreement to commercialize the University’s biosensor technology as a medical diagnostic tool for research labs and point-of-care health professionals.
“The biosensor technology, which can be applied in the development of a variety of new and innovative sensing equipment, has the capability of revolutionizing medical diagnostics,” said MTSU professor Bill Robertson, the inventor and member of the Department of Physics and Astronomy faculty.
An interdisciplinary team from MTSU including Drs. Robertson, Steve Wright (biology), and Andrienne Frirdli (chemistry) developed the new technology with support from the National Science foundation and Department of Homeland Security.
“The growth of personalized Medicine creates a pressing need for faster and better ways of diagnosing diseases and individual responses to pharmaceutical treatment,” he added. “In addition, drug discovery can be shortened when a rapid (and) more accurate way of screening for biological changes can be used in the process.”
The technology is based on specially designed multilayers, alternating thin films of silicon dioxide and titanium dioxide of precise thickness coated on a glass microscope slide. These multilayers support electromagnetic waves that travel along the surface and detect extremely small changes, such as the addition of one layer of protein or antibody molecules on the slide surface.
On appropriately prepared slides, such changes could indicate the identifiable markers of specific diseases.
“With the increase of disease-resistant bacteria and new stains of viruses killing over 700,000 people worldwide each year, speeding up the drug discovery process is an urgent priority,” Robertson said.
Dr. Nabil El-Hag, Tecport’s Vice Chairman and architect of the strategic relationship, said, “The long-term goal is to use biosensor technology as a mainstay in point-of-care medical diagnostics, not only in doctors’ offices and clinics, but in the local drugstore. This represents an opportunity to participate in the fast-growing $40 billion-plus medical diagnostic market.
“In Third World countries, where access to healthcare is often inaccessible, out biosensor technology could speed up and reduce the cost of diagnosis and treatment,” he said.
Tecport’s “cold palsma” thin film technology allows affordable fabrication of the multilayers, so that they can be used as a disposable supply for a biosensor.
Dr. Nabil El-Hag Rejoins Tecport Optics as Vice Chairman
March 7, 2016 — Tam Le, Founder and Chairman of Tecport Optics, today announced the appointment of Dr. Nabil El-Hag as Vice-Chairman of the company. “We are pleased that Dr. El-Hag has rejoined our company. He will be working closely with me on setting the strategic direction of the company, including the development of new strategic alliances that support our growth strategy. Dr. El-Hag was the architect and driving force for establishing our joint venture with the University of Utah and Axon Corporation a few years ago. He crafted the alliance that enabled us to deploy our cold plasma technology for lens applications for the treatemnt of light sensitive migraine headaches,” said Mr. Le.
The products developed by Axom and Tecport have now reached the final FDA approval stage and Tecport is mobilizing their resources to capitalize on this opportunity. The US migrain market is currently estimated at $2 billion in prescription drug sales. According to a 2001 NIH report, approximately 28 million people suffer from migraines in the US, more than diabetes and asthma combined.
The application of Tecport’s “Polaris Process” is an industry break-through that allows multi-layer thin film coating on plastics. This cold plasma technology opens up a myriad of business opportunities across many market segments. “I am pleased to be working with Tecport during this exciting stage of their growth, and look forward to establishing the strategic alliances that will enable them to capitalize on this revolutionary development in optical technology,” comment Dr. El-Hag.
Dr. El-Hag, an accomplished Fortune 500 executive, an experienced entrepreneur, an award winning scientist, brings over 35 years of unique experience to the venture. “His balanced approach to building value through win-win partnerships, has served us well in the past,” said Mr. Le. “We are confident that Dr. El-Hag’s leadership and business acumen will enable us to realize the tremendous opportunities that cold plasma technology brings to our industry.”
New DLC Coating System – The Rock
Tecport is proud to announce the newest system to their award winning lineup, the Rock. The Rock offers
- Multilayer coating with DLC top coat
- Planetary bias substrate rotation system
- SP3 highly transparent optical DLC coating
How Can We Serve You?